Bio2 Gains Approval to Study Vitrium in Interbody Fusion

Bio2 Technologies received FDA approval to commence enrollment in an Investigational Device Exemption clinical study of Vitrium bioactive glass as a structural cervical interbody fusion device.

Vitrium is presently FDA 510(k) cleared for marketing as a bone graft substitute. This one-year randomized, controlled, non-inferiority pivotal study...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us